高雄醫學大學癌症研究中心 - Chief

Li-Tzong Chen, M.D., Ph.D.

Education

1975.8 - 1982.7	M.D. Kaohsiung Medical College, Kaohsiung, Taiwan
1992.8 – 2001.7	Ph.D. Post-graduate School, Kaohsiung Medical University

Current Position

1988.08-	Attending Physician, Division of Gastroenterology, Department of Medicine, Kaohsiung Medical University Hospital
2012.08-	Adjunct Professor of Internal Medicine, Medical School, National Cheng Kung University, Tainan, Taiwan
2007.07-	Attending Physician, Department of Internal Medicine, National Cheng-Kung University Hospital
2014.08-	Director, National Institute of Cancer Research, National Health Research Institutes
2020.08-	Co-affiliated, Distinguished Investigator, National Health Research Institutes
2020.08-	Chair Professor of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
2020.08-	Chief Executive Officer of Center for Cancer Research, Kaohsiung Medical University
2020.08-	Chairperson, Research and Development Committee, Kaohsiung Medical University Chung-Ho Memorial Hospital

Experience

1992.08 - 2005.01	Lecturer of Internal Medicine. Kaohsiung Medical University
1995.08 –2009.09	Adjunct Attending Physician, Department of Oncology, National Taiwan University Hospital, Taipei
1995.08 –2006.07	Adjunct Attending Physician, Department of Internal Medicine, Veteran General Hospital, Taipei
2002.08 - 2005.12	Associate Investigator, National Health Research Institutes
2005.02–2012.07	Associate Professor, College of Medicine, Kaohsiung Medical University
2006.01–2014.07	Investigator, National Institute of Cancer Research, National Health Research Institutes
2006.08 –2007.07	Adjunct Attending Physician, Department of Internal Medicine, Tri-service General Hospital, Taipei
2008.03 –2018.07	Adjunct Professor, Institute of Clinical Pharmacy and Pharmaceutical Science, National Cheng Kung University, Tainan
2008.03 –2012.08	Deputy Director, National Institute of Cancer Research, National Health Research Institutes
2012.09 - 2018.07	(Adjunct) Professor of Internal Medicine, College of Medicine, Kaohsiung Medical University
2012.09 -2013.07	Vice Superintendent and Director of Cancer Centre, Kaohsiung Medical University Hospital, Kaohsiung Medical University
2013.08 –2014.07	Acting Director, National Institute of Cancer Research, National Health Research Institutes
2014.08 - 2020.07	Distinguished Investigator, National Health Research Institutes
2018.08 - 2020.07	Adjunct (Co-affiliated), Chair Professor of Internal Medicine, College of Medicine, Kaohsiung Medical University

Honors / Awards

2014	Outstanding Clinical Research Award, 24th Wang Ming-Ning Memorial Foundation Award (王民寧基金會: 對醫藥科技發展、國民健康和國家社會傑出貢獻獎), Taipei, Taiwan, December 19th, 2014.
2015	Outstanding Research Award, Ministry of Science and Technology (科技部傑出研究獎), Taipei, Taiwan, May 2^nd, 2015.
2015	Outstanding Research Award, Association of Kaohsiung Medical University Alumni (高雄醫學大學傑出校友獎-學術類), Kaohsiung, Taiwan, October 18^th, 2015.
2017	Outstanding Biomedical & Biotechnology Award, 12th TienTe Lee Biomedical Foundation (李天德醫藥基金會:卓越醫藥科技獎), Taipei, Taiwan, May 2017.
2018	Outstanding Research Award, Ministry of Science and Technology (科技部傑出研究獎), Taipei, Taiwan, May 28^th, 2018.
2018	Gold Medal Award, Technology Transfer Award, 2018 BioTaipei Award (台北生技獎技轉金牌獎), Bio@Taipei, Taipei, Taiwan, July 20, 2018.
2019	6^th National Industrial Innovation Award – Innovative Elite Award – Industrial Contribution (Individual Category), Ministry of Economic Affair, ROC. (第六屆經濟部國家產業創新獎個人類-創新菁英-產學貢獻), Taipei, Taiwan, April 10, 2019.

Recent Publications (2020)

1	Chiang NJ, Tsai KK, Hsiao CF, Yang SH, Hsiao HH, Shen WC, Hsu C, Lin YL, Chen JS, Shan YS, Chen LT. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma -TCOG T1211 study. Eur J Cancer* 2020 Jan;124:123-130.
2	Macarulla Mercadé T, Chen LT, Li CP, Siveke JT, Cunningham D, Bodoky G, Blanc JF, Lee KH, Dean A, Belanger B, Wang-Gillam A. Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial. Pancreas.* 2020 Jan;49(1):62-75
3	Bang YJ, Li CP, Lee KH, Chiu CF, Park JO, Shan YS, Kim JS, Chen JS, Shim HJ, Rau KM, Choi HJ, Oh DY, Belanger B, Chen LT. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: subgroup analysis of the NAPOLI-1 study. Cancer Sci* 2020 Feb;111(2):513-527.
4	Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho CF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol* 2020 Mar;31(3):334-351
5	de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang CH, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DCL, Bogenrieder T, Twelves C and Cheng AL. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. Br J Cancer 2020 Apr;122(9):1324-1332
6	AC Roy, J Shapiro, M Burge, C Karapetis, N Pavlakis, E Segelov, I Chau, F Lordick, LT Chen, A Barbour, N Tebutt, T Price. Management of early stage gastro-oesophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy 2020 Apr;20(4):305-324 [2018 IR, 8.676]
7	Shan YS^＃, Chen LT^＃, Wu JS^＃, Chang YF, LeeCT, WuCH, ChiangNJ, HuangHE, Yen CJ, ChaoYJ, TsaiHJ, ChenCY, KangJW, Kuo CF, Tsai CR, Weng YL, Yang HC, Liu HC, Chang JS. Validation of genome-wide association study-identified single nucleotide polymorphisms in a case-control study of pancreatic cancer from Taiwan. J Biomed Sci 2020 May 26;27(1):69 (# co-first authors)
8	Su YY, Chiang NJ, Tsai HJ, Yen CJ, Shan YS, Chen LT. The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: real-world experience in a Taiwanese cohort. Sci Report* 2020 May;10(1):7420
9	Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Kang YK, Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer* 2020 May; 23(3): 510-519
10	Chiang NJ, Chen MH, Yang SH, Hsu C, Yen CJ, Tsou HH, Su YY, Chen JS, Shan YS, Chen LT. Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study. Liver Int* 2020.05 (online published) doi: 10.1111/liv.14538.
11	Yoo CH, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osda M, Helwig C, Dussault I, Ikeda M. Phase 1 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in Asian patients with pre-treated biliary tract cancer. J Immunother Cancer 2020* May;8(1):e000564
12	Tsa HJ^#, Dai JJ, Chen LT^#, Wu MS, Yeh KH, Lin CW, Wang TE, Wang SP, Yu FJ, Liou JM, Hsiao CF, Cheng TY, Yeh HJ, Ko CW, Chen MJ, Lo GH, Hsu PI, Chang CS, Hwang WS, Chuang SS, Lee HW, Shun CT, Chiu CF, Wang WM, Hsieh CY, Liu TW, Lin JT, Kuo SH#, Cheng AL. A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. Hematologica 2020 Jul;105(7):e349-e354 (#co-first author)